股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額 ...

白 皮 书 + 奖 项 + 论 坛 | 第 二 届 全 球 心 血 管 大 会 心未来 2026年2月27日，国家药品监督管理局（NMPA）通过创新医疗器械特别审查程序，批准上 海微创医疗器械（集团）有限公司（以下简称"微创®冠脉"）旗下的 上 海微创旋律医疗科技有限公司 的 全球首创产品 —— FireSpear™/火锋™压电式冠脉血管内超声治疗系统 上市（国械注准20263010405、国械注准 20263010406）。 在冠脉复杂病变持续受到关注的背景下，这一技术路径的落地，意味着国产企业在 慢性完全闭塞 细分领域迈出新的探索步伐。 # CTO ： PCI 体系中的高难度板块 慢性完全闭塞 （Chronic Total Occlusion， CTO ）是指血管（常见于冠状动脉、外周动脉等）因 长期病变导致管腔完全堵塞，且闭塞时间通常超过3个月的 一种病理状态 。 | 索引号 | XZXK-2026-10036 | 主题分类 | | --- | --- | --- | | 标题 | 血管内超声治疗设备和一次性使用冠脉血管内超声导丝获批上市 | | | 发布日期 | 2026-02-27 | | | 发布 ...

证券之星消息，2月27日南向资金减持13.41万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持168.96万股。近20个交易日中，获南向资金增持的有14天，累计净增持 1470.22万股。截至目前，南向资金持有微创医疗（00853.HK）9.26亿股，占公司已发行普通股的 48.28%。 微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - MicroPort Medical (00853) reported HeartCare Medical (688016.SH) 2025 annual performance forecast, showing total revenue of approximately 1.351 billion yuan, a year-on-year increase of 11.96%, and a net profit attributable to the parent company of approximately 563 million yuan, a year-on-year increase of 12.17% [1] Group 1: Financial Performance - Total revenue for the year is approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - Net profit attributable to the parent company is approximately 563 million yuan, with a year-on-year increase of 12.17% [1] - Basic earnings per share stand at 4.65 yuan [1] Group 2: Market Strategy and Sales - The company has strengthened its domestic leading position through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of total revenue [1] - The company is actively promoting its products in Europe, Latin America, and Asia-Pacific, with sales coverage extending to 49 countries and regions [1] Group 3: Product Development and Approvals - Multiple innovative products have been approved for launch in China, including the Cratos branched aortic stent graft system and other medical kits [2] - A total of 23 products have received NMPA registration, and 11 products have been registered in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products entering various stages of clinical trials and regulatory submissions [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 海外監管公告 常兆華博士 主席 本海外監管公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.10B條刊 發。 請參閱隨附上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）於上海證券交易所科創板 （「科創板」）刊發之公告（「該公告」），內容有關其二零二五年年度業績快報公告。 心脈醫療科技為一家於科創板上市之公司。於本公告日期，本公司持有心脈醫療科技已發行股本約 40.32%及其業績於本公司財務報表合併入賬。 於聯交所網站登載該公告，僅為向香港投資者進行同等的資訊傳達及遵守上市規則第13.10B條，別 無其他目的。 承董事會命 中國上海，二零二六年二月二十七日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為谷峰博士、門慶兵博士及 孫維琴女士；及本公司之獨立非執行董事為 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On February 26, southbound funds increased their holdings by 1.6111 million shares of MicroPort Scientific Corporation [1] - Over the past five trading days, there have been four days of net increases, totaling 2.4247 million shares [1] - In the last 20 trading days, there were 15 days of net increases, amounting to 18.428 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Scientific Corporation, representing 48.28% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business Division, which includes implantable devices and access devices [1] - Orthopedic Medical Devices Business Division, focusing on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM) Business Division, which includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business Division, featuring products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business Division, dealing with cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business Division, which includes transcatheter aortic valve implantation [1] - Surgical Robotics Business Division, involved in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices Business Division, focusing on the manufacturing and R&D of surgical medical devices [1]

Core Viewpoint - Southbound funds increased their holdings in MicroPort Scientific Corporation (00853.HK) by 242,100 shares on February 23, indicating a positive sentiment towards the company despite some fluctuations in the previous trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 915,800 shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 15 days, with a cumulative net increase of 16,929,900 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 1.4415 million shares on February 13, with net increases recorded on 4 out of the last 5 trading days, totaling 676,500 shares [1] - Over the past 20 trading days, there have been net increases on 15 days, amounting to 20.3817 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Medical, representing 48.26% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM): Includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Features products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Involves products for carotid artery atherosclerosis and coils [1] - Structural Heart Disease Business: Engages in transcatheter aortic valve implantation [1] - Surgical Robotics Business: Manufactures and develops surgical robotic devices [1] - Surgical Medical Devices Business: Focuses on the manufacturing and R&D of surgical medical devices [1]

智通财经APP获悉，香港联交所最新数据显示，2月9日，摩根大通增持微创医疗(00853)89.1713万股， 每股作价11.089港元，总金额约为988.82万港元。增持后最新持股数目约为1.92亿股，持股比例为 10.02%。 ...